News

December 6, 2019

CHMP Favors Kadcyla Approval in EU for Certain HER2-positive Early Breast Cancer Patients

News

The Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency, has recommended that Kadcyla (ado-trastuzumab emtansine) be approved as an adjuvant (post-surgery) treatment for certain ... Read more

December 4, 2019

Weight Loss Surgery May Lower Risk of Breast Cancer, Research Suggests

News

Weight loss surgery may reduce the risk of developing breast cancer in obese individuals, even among those with a genetic predisposition towards cancer, new research suggests. The research was ... Read more

November 15, 2019November 15, 2019

More Than $850M Raised for Inflammatory Breast Cancer Research

News

Susan G. Komen, the Inflammatory Breast Cancer (IBC) Research Foundation, and the Milburn Foundation have joined to raise more than $850,000 for research targeting innovative diagnostic tools and therapy ... Read more

November 13, 2019

Fertility Clinics and Breast Cancer ‘Previvor’ Team Up to Raise Awareness About Genetic Risk of Disease

News

For patients with gene mutations that increase their risk for diseases such as breast cancer, fertility and in vitro fertilization (IVF) center Shady Grove Fertility (SGF) is offering individualized testing ... Read more

November 11, 2019November 11, 2019

Blood Test May Identify Breast Cancer Years Before Symptoms Appear, Pilot Study Suggests

News

A simple blood test – which measures antibodies against certain tumor proteins, or antigens — may identify breast cancer up to five years before clinical signs of cancer are ... Read more

November 8, 2019November 8, 2019

Most Breast Cancers Found by Hand, MammaCare Researchers Say

News

Decades after establishing the recognized standard for performing and teaching clinical and personal breast exams, the MammaCare Foundation wants women and others to be aware that most breast cancers ... Read more

November 6, 2019

First Patient Dosed in Phase 3 Trial of Tucatinib-Kadcyla Combo for Advanced HER2-Positive Breast Cancer

News

A Phase 3 trial exploring a combination of Seattle Genetics‘ tucatinib plus standard Kadcyla (ado-trastuzumab emtansine) in people with advanced HER2-positive breast cancer has dosed its first participant, the ... Read more

November 4, 2019

Hormone Therapy Has More Long-term Impact on Quality of Life Than Chemo, Study Suggests

News

Challenging conventional wisdom, new findings suggest that hormone therapy may have a greater impact than chemotherapy on long-term quality of life in women with breast cancer, particularly those who ... Read more

November 1, 2019

Pathologist Creates Program Allowing Patients to Face Their Cancer Head-on

News

Massachusetts pathologist Lija Joseph, MD, has created an innovative program that allows patients, including those with breast cancer, to actually see the cells that make up their malignancies. In ... Read more

October 30, 2019

Seattle Genetics’ Tucatinib Extends Survival Outcomes in Metastatic HER2-positive Breast Cancer Patients, Phase 2 Trial Shows

News

People with HER-positive advanced breast cancer who received multiple HER-targeted therapies have significantly better survival outcomes — including overall survival and survival without disease progression — when given a ... Read more

Pin It on Pinterest